Table 2. Comparison of HIV-Related Characteristics and Cumulative ARV Exposure in HIV-infected Subjects with and without Albuminuria.

	Albuminuria (n = 36)	No Albuminuria (n = 119)	p-value
Duration HIV (y)	13.1±1.0	13.7±0.6	0.6
Duration ARV exposure (y)	7.4±0.9	7.9±0.4	0.6
CD4 T cell count	498±42	570±26	0.15
HIV viral load (log copies/ml)	2.55±0.2	2.10±0.08	0.046
Cumulative NRTI Exposure
Abacavir (mos)	30±7	11±2	0.01
Didanosine (mos)	15±6	11±2	0.6
Emtricitabine (mos)	8±2	12±2	0.09
Lamivudine (mos)	53±8	63±4	0.3
Stavudine (mos)	21±6	21±3	0.99
Tenofovir (mos)	19±4	22±2	0.5
Zalcitabine (mos)	4±2	1±0.2	0.2
Zidovudine (mos)	30±6	42±4	0.09
Cumulative PI Exposure
Atazanavir (mos)	7±2	8±1	0.6
Indinavir (mos)	6±3	15±3	0.01
Lopinavir (mos)	13±4	14±2	0.8
Nelfinavir (mos)	13±5	12±2	0.9
Ritonavir (mos)	19±5	16±2	0.6
Saquinavir (mos)	5±2	3±1	0.5
Cumulative NNRTI Exposure
Efavarenz (mos)	19±5	22±3	0.6
Nevirapine (mos)	12±5	8±2	0.5